These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 1378140)

  • 21. Comparison of the effects of carvedilol and nifedipine in patients with essential hypertension and non-insulin-dependent diabetes mellitus.
    Albergati F; Paternó E; Venuti RP; Boeri D; Lombardo I; Semino S; Viviani GL; Adezati L
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S86-9. PubMed ID: 1378156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of combining extended-release carvedilol and lisinopril in hypertension: results of the COSMOS study.
    Flack JM
    J Clin Hypertens (Greenwich); 2010 Sep; 12(9):664-5. PubMed ID: 20928961
    [No Abstract]   [Full Text] [Related]  

  • 23. Enantioselective pharmacokinetic-pharmacodynamic modelling of carvedilol in a N-nitro-l-arginine methyl ester rat model of secondary hypertension.
    Di Verniero CA; Bertera F; Buontempo F; Bernabeu E; Chiappetta D; Mayer MA; Bramuglia GF; Taira CA; Höcht C
    J Pharm Pharmacol; 2010 Jul; 62(7):890-900. PubMed ID: 20636877
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemodynamic effects of carvedilol after acute oral administration in hypertensive and normal subjects.
    Cournot A; Lim C; Duchier J; Safar M
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S35-9. PubMed ID: 1378147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antihypertensive treatment with a vasodilating beta-blocker, carvedilol, in chronic hemodialysis patients.
    Deetjen A; Heidland A; Pangerl A; Meyer-Sabellek W; Schaefer RM
    Clin Nephrol; 1995 Jan; 43(1):47-52. PubMed ID: 7697935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Efficacy of native carvedilol in patients with essential hypertension].
    Yang T; Zhang Z; Jia Z; Lin S; Peng Y
    Hunan Yi Ke Da Xue Xue Bao; 1999; 24(2):153-6. PubMed ID: 11938776
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
    Lund-Johansen P; Omvik P; Nordrehaug JE; White W
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic haemodynamic effects of carvedilol in essential hypertension at rest and during exercise.
    Lund-Johansen P; Omvik P
    Eur Heart J; 1992 Feb; 13(2):281-6. PubMed ID: 1555629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with carvedilol is associated with a significant reduction in microalbuminuria: a multicentre randomised study.
    Fassbinder W; Quarder O; Waltz A
    Int J Clin Pract; 1999; 53(7):519-22. PubMed ID: 10692737
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study.
    Fogari R; Zoppi A; Poletti L; Marasi G; Mugellini A; Corradi L
    Am J Hypertens; 2001 Jan; 14(1):27-31. PubMed ID: 11206674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dose-effect relationship of carvedilol in essential hypertension. An open study.
    Ogihara T; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T; Arakawa K
    Drugs; 1988; 36 Suppl 6():75-81. PubMed ID: 2908305
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of early carvedilol treatment and withdrawal on the development of hypertension and renal vascular narrowing.
    Kett MM; Denton KM; Boesen EI; Anderson WP
    Am J Hypertens; 2004 Feb; 17(2):161-6. PubMed ID: 14751659
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up of a method of twenty-four-hour indirect blood pressure monitoring: evaluation of carvedilol, a new antihypertensive agent.
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    Nephron; 1987; 47 Suppl 1():42-6. PubMed ID: 3320788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart failure in a district general hospital: are target doses of beta-blockers realistic?
    Mehta PA; McDonagh S; Poole-Wilson PA; Grocott-Mason R; Dubrey SW
    QJM; 2004 Mar; 97(3):133-9. PubMed ID: 14976270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute and 14-day hepatic venous pressure gradient response to carvedilol and nebivolol in patients with liver cirrhosis.
    Silkauskaitė V; Kupčinskas J; Pranculis A; Jonaitis L; Petrenkienė V; Kupčinskas L
    Medicina (Kaunas); 2013; 49(11):467-73. PubMed ID: 24823927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circadian antihypertensive profile of carvedilol (BM 14190).
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S119-23. PubMed ID: 2454357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and efficacy of carvedilol in chronic hemodialysis patients with hypertension.
    Miki S; Masumura H; Kaifu Y; Yuasa S
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S62-8. PubMed ID: 1721982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of carvedilol on left ventricular function and mass in hypertension.
    Why HJ; Richardson PJ
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S50-4. PubMed ID: 1378151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension.
    Giugliano D; Marfella R; Acampora R; Giunta R; Coppola L; D'Onofrio F
    Diabetes Care; 1998 Apr; 21(4):631-6. PubMed ID: 9571355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.